Ribaxamase, an Orally Administered β-Lactamase, Diminishes Changes to Acquired Antimicrobial Resistance of the Gut Resistome in Patients Treated with Ceftriaxone

INTRODUCTION: Intravenous (IV) β-lactam antibiotics, excreted through bile into the gastrointestinal (GI) tract, may disrupt the gut microbiome by eliminating the colonization resistance from beneficial bacteria. This increases the risk for Clostridium difficile infection (CDI) and can promote antim...

Descripción completa

Detalles Bibliográficos
Autores principales: Kokai-Kun, John F, Le, Chenxiong, Trout, Kenneth, Cope, Julia L, Ajami, Nadim J, Degar, Andrew J, Connelly, Sheila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383106/
https://www.ncbi.nlm.nih.gov/pubmed/32801790
http://dx.doi.org/10.2147/IDR.S260258

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383106/
https://www.ncbi.nlm.nih.gov/pubmed/32801790
http://dx.doi.org/10.2147/IDR.S260258

Ejemplares similares